Pengaruh Pemberian Active Hexose Correlated Compound® (AHCC®) Terhadap Response Evaluation Criteria in Solid Tumours (RECIST) pada Pasien Kanker Paru Jenis Karsinoma Bukan Sel Kecil (KPKBSK) yang Menjalani Kemoterapi

Abstract

Background: Non small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality, with most patients diagnosed at advanced stages and treated with systemic chemotherapy. Response Evaluation Criteria in Solid Tumours (RECIST) is the standard method for assessing tumor response. Active Hexose Correlated Compound® (AHCC®), a mushroom-derived supplement with immunomodulatory properties; however, clinical evidence regarding its effect on RECIST outcomes in NSCLC patients remains limited, particularly in Indonesia. Objective: To analyze the effect of AHCC® supplementation on tumor response based on RECIST criteria in patients with NSCLC undergoing chemotherapy. Methods: This study was an analytic quasi-experimental study. Subjects were divided into 50 NSCLC patients consist of AHCC® group and a placebo group receiving chemotherapy at three hospitals in Medan. Tumor response was evaluated at baseline, after the third cycle, and after the sixth cycle of chemotherapy. Results: No statistically significant difference was found between AHCC® and placebo groups in RECIST response at cycle three (p=0.565) or cycle six (p=0.635). Conclusion: AHCC® supplementation did not demonstrate a statistically significant effect on tumor response based on RECIST criteria in NSCLC patients undergoing chemotherapy. Further studies with larger sample sizes and longer follow-up periods are warranted to clarify the potential clinical benefits of AHCC®.